MONTCLAIR, N.J., Nov. 26, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST) today announced the October 31, 2012 online publication of "Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients" in Breast Cancer Research, an international, peer-reviewed online journal. Dr. John S. Condeelis, Chairman of MetaStat's Scientific Advisory Board, is senior on the publication. Dr. Condeelis holds The Judith and Burton P. Resnick Chair in Translational Research and is Professor and Co-Chair of the Department of Anatomy and Structural Biology and co-Director of the Gruss Lipper Biophotonics Center at Albert Einstein College of Medicine of Yeshiva University. He is also leader of the Tumor Microenvironment and Metastasis program in the Albert Einstein Cancer Center.
The publication describes MetaStat's licensed proprietary technology to genetically profile and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a breast cancer tumor. This was made possible by the Company's proprietary method to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature, thus actually isolating and collecting these deadly metastatic cells.
Currently available genome-wide studies attempt to provide prognostic information on the probability of cancer recurrence. However, these studies are less than optimal in predicting metastatic outcome because they genetically profile whole tumor tissue without respect to the fact that only a small subpopulation of metastatic cells inside the primary tumor is responsible for escaping and initiating dissemination and metastasis. When whole tumor tissue is used for genetic profiling, the expression pattern of these metastatic cells is masked by the presence of a vast majority of noninvasive tumor cells and undefined stromal cells. Therefore, little information is available about the crucial early steps of metastasis. Mr. Warren C. Lau, President and CEO of MetaStat stated "We are pleased with the conclusions from this publication that show the novel markers identified here might become valuable prognostic tools and therapeutic targets in breast cancer."
MetaStat intends to develop next generation metastasis diagnostic products based on this and our other proprietary technologies.
A copy of the publication can be found on the Breast Cancer Research website using the following URL: http://breast-cancer-research.com/content/14/5/R139/abstract
About MetaStat, Inc.
MetaStat was formed to help cancer patients benefit from recent discoveries in how cancer spreads through the bloodstream to other organs in the body in a process called systemic metastasis. We believe our MetaSite Breast™ and MenaCalc™ diagnostic product lines will accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and/or radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because 90% of all solid tumor cancer deaths are due from metastasis.
Additionally, we believe our MenaBloc™ technology provides us with targets of intervention in key pathways for the development of targeted therapeutics that may preemptively reduce or eliminate metastasis in these tumor types.
Our technology platform(s) and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace. Our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo, which enabled us to specifically isolate and thus characterize the behavior, mechanics and genetics of these highly metastatic cancer cells.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
For More Information,
Warren C. Lau
President & CEO
SOURCE MetaStat, Inc.